Metraipolis › archive › dc_551dae3aa5a2

Risk of interstitial lung disease in non-small cell lung cancer treated with EGFR-TKI: a real-world pharmacovigilance study — Europe PMC PMID:40949116

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40949116
DOI
10.3389/fphar.2025.1652750
License (as archived)
solo-consultazione
Archived
2026-11-10T06:32:14.364Z
SHA-256 of the archived text
f13d20db5e969212e06869f7322c71c02398ce908fde71d43b37a2e0ad84903f
Stable URL of this page
https://metraipolis.com/documento/dc_551dae3aa5a2

How to cite

Risk of interstitial lung disease in non-small cell lung cancer treated with EGFR-TKI: a real-world pharmacovigilance study — Europe PMC PMID:40949116 — Europe PMC (en), https://europepmc.org/article/MED/40949116 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_551dae3aa5a2 (Metraipolis archive dc_551dae3aa5a2, sha256 f13d20db5e969212e06869f7322c71c02398ce908fde71d43b37a2e0ad84903f)
BibTeX
@misc{dc551dae3aa5a2,
  title = {Risk of interstitial lung disease in non-small cell lung cancer treated with EGFR-TKI: a real-world pharmacovigilance study — Europe PMC PMID:40949116},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40949116},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_551dae3aa5a2; sha256 f13d20db5e969212e06869f7322c71c02398ce908fde71d43b37a2e0ad84903f},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40949116. Agents can read the archived copy with the MCP tool read_document.